Last reviewed · How we verify
Fosrenol (Lanthanum Carbonate)
Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.
Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels. Used for Hyperphosphatemia in patients with chronic kidney disease on dialysis, Hyperphosphatemia in patients with chronic kidney disease not on dialysis.
At a glance
| Generic name | Fosrenol (Lanthanum Carbonate) |
|---|---|
| Also known as | FOSRENOL |
| Sponsor | Shire |
| Drug class | Phosphate binder |
| Target | Dietary phosphate (non-receptor target) |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
Lanthanum is a rare earth element that acts as a phosphate binder in the GI tract. It dissociates to release lanthanum ions, which form highly insoluble lanthanum phosphate complexes with dietary phosphate. This prevents phosphate absorption and reduces serum phosphate concentrations in patients with chronic kidney disease and hyperphosphatemia.
Approved indications
- Hyperphosphatemia in patients with chronic kidney disease on dialysis
- Hyperphosphatemia in patients with chronic kidney disease not on dialysis
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Constipation
Key clinical trials
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (PHASE4)
- Healthy Combine Study (PHASE1)
- The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease (NA)
- Phosphate Lowering in CKD Trial (PHASE4)
- The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE (PHASE2)
- To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder (PHASE1, PHASE2)
- Different Effects of Non-calcium Phosphate Binders on Serum Calcium (PHASE4)
- Long-term Effect of Lanthanum Carbonate on Bone
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fosrenol (Lanthanum Carbonate) CI brief — competitive landscape report
- Fosrenol (Lanthanum Carbonate) updates RSS · CI watch RSS
- Shire portfolio CI